or Try an Advanced Search...

    Companion Diagnostic Stocks List

    Symbol Grade Name % Change
    BDSX D Biodesix, Inc. 6.87
    MACK B Merrimack Pharmaceuticals, Inc. -0.20
    MYGN D Myriad Genetics, Inc. 1.30
    QGEN C Qiagen N.V. 0.70
    VSTM D Verastem, Inc. 5.21
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research
    Related Stock Lists: Biopharmaceutical Cancer Medicine Biology Biotechnology Breast Cancer Lab Testing Medical Research Ovarian Cancer Treatment Of Breast Cancer mTOR Acid Advanced Cancer Advanced Cancers Antibodies Biomarkers Breast And Ovarian Cancer Cancer Cell Cancer Research Cancer Stem Cell

    Related ETFs - A few ETFs which own one or more of the above listed Companion Diagnostic stocks.

    Symbol Grade Name Weight
    GNOM D Global X Genomics & Biotechnology ETF 6.95
    PBE C PowerShares Dynamic Biotech & Genome 4.98
    EKG D First Trust Nasdaq Lux Digital Health Solutions ETF 4.67
    WDNA D WisdomTree BioRevolution Fund 2.18
    BBH B Market Vectors Biotech ETF 2.01
    View all Companion Diagnostic ETFs...
    Compare ETFs
    Compare EKG to WDNA Compare GNOM to PBE Compare PBE to BBH

        Companion Diagnostic Stocks Recent News

        Date Stock Title
        May 2 QGEN QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
        May 2 QGEN Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next
        May 1 QGEN Qiagen N.V. (NYSE:QGEN) Q1 2024 Earnings Call Transcript
        May 1 QGEN Qiagen First Quarter 2024 Earnings: EPS Beats Expectations
        Apr 30 MACK Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq
        Apr 30 MACK Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
        Apr 30 MYGN Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
        Apr 30 QGEN Qiagen N.V. 2024 Q1 - Results - Earnings Call Presentation
        Apr 30 QGEN Qiagen N.V. (QGEN) Q1 2024 Earnings Call Transcript
        Apr 30 QGEN QIAGEN (QGEN) Q1 Earnings Top Estimates, Margins Expand
        Apr 29 QGEN Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings
        Apr 29 QGEN Qiagen (QGEN) Surpasses Q1 Earnings and Revenue Estimates
        Apr 29 QGEN Qiagen Non-GAAP EPS of $0.46 beats by $0.02, revenue of $459M beats by $2.09M
        Apr 29 QGEN QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
        Apr 29 QGEN US Stocks Set To Approach New Week With Caution Ahead Of Fed Meeting, Tech Earnings: Analyst Says 'Buy The Dip' Contingent On This Condition
        Apr 29 QGEN Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
        Apr 28 QGEN Qiagen Q1 2024 Earnings Preview
        Related Industries: Biotechnology Diagnostics & Research
        Related Stock Lists: Biopharmaceutical Cancer Medicine Biology Biotechnology Breast Cancer Lab Testing Medical Research Ovarian Cancer Treatment Of Breast Cancer mTOR Acid Advanced Cancer Advanced Cancers Antibodies Biomarkers Breast And Ovarian Cancer Cancer Cell Cancer Research Cancer Stem Cell
        Companion Diagnostic

        Companion diagnostics are tests used to identify which patients are most likely to benefit from a particular therapy. They are used to identify the presence or absence of a biomarker that is associated with a particular disease or condition, and to determine the best course of treatment for a patient. Companion diagnostics are used to help physicians make more informed decisions about which treatments are most likely to be effective for a particular patient.

        Browse All Tags